Overview Bioequivalence Study Comparing Artesunate Tablet To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects Status: Completed Trial end date: 2009-08-01 Target enrollment: Participant gender: Summary The study will determine if artesunate tablet (Pfizer), an antimalarial agent, is pharmaceutically equivalent to Arsuamoon® tablets (Guilin-China). Phase: Phase 1 Details Lead Sponsor: PfizerTreatments: ArtemisininsArtesunate